Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

Conclusion:To our knowledge this is the first population-based study of clonal hematopoiesis in patients with lymphoma. We find that CHIP and particularly mutations in DNA damage response genes (PPM1D/TP53) are associated with increased mortality, which confirms findings from single center studies. These data support the evaluation of CHIP for risk assessment in lymphoma patients before high-dose chemotherapy. Our study also identifies increased rates of several clinically relevant adverse outcomes (severe infections, blood transfusions and secondary cancers) in lymphoma patients with clonal hematopoiesis.Figure 1.DisclosuresGrønbæk: Janssen Pharma: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Otsuka Pharma: Membership on an entity's Board of Directors or advisory committees.

Source: Blood - November 21, 2018 Category: Hematology Authors: Husby, S., Francesco, F., Nielsen, C., Sorensen, B., Baech, J., Hansen, J. W., Gonzalez, G. G. R., Arboe, B., Andersen, L. P., Hastrup, E. K., Fischer-Nielsen, A., Saekmose, S. G., Hansen, P. B., Christiansen, I., Clasen-Linde, E., Knudsen, L. M., Grell, Tags: 731. Clinical Autologous Transplantation: Results: Autologous Transplantation: Clonal Hematopoiesis, Microbiota, AML, NHL, and Autoimmune Diseases Source Type: research